


BIOLINE PRODUCTION LIMITED

Unaudited Financial Statements

For the 9 months ended 30 June 2022

Registered Number: 02050016



VP

BIOLINE PRODUCTION LIMITED

Registered number: 02050016

FINANCIAL STATEMENTS

for the 9 months ended 30 June 2022

Contents

Page No

2	Company summary
3	Directors' report
4	Statement of financial position
6-7	Notes to the financial statements



BIOLINE PRODUCTION LIMITED

Registered number: 02050016

COMPANY SUMMARY

Directors

M Fournier
Mt L Martel
Mr L Pokorny

Secretary

Eriska Secretaries Limited

Registered Office

Telstar Nursery
Holland Road
Little Clacton
Essex
CO16 9QG



BIOLINE PRODUCTION LIMITED

Registered number: 02050016

DIRECTORS' REPORT for the 9 months ended 30 June 2022

The directors present their report and the unaudited financial statements of the company for the 9 months ended 30 June 2022. The company has been dormant as defined in section 1169 of the Companies Act 2006 throughout the period. It is anticipated that the company will remain dormant for the foreseeable future.

Directors

The directors whose names appear on page 2 of this report were directors of the company during the period and remain so at the date of the report (unless stated otherwise).

This report was approved by the board of directors on
and signed on behalf of the board by:



L. POKORNY
Director

BIOLINE PRODUCTION LIMITED

Registered number: 02050016

STATEMENT OF FINANCIAL POSITION as at 30 June 2022

	Note	30 June 2022	30 September 2021
		£	£
Fixed assets			
Tangible fixed assets		-	-
Current assets			
Debtors	2	176,539	176,539
Cash at bank and in hand		-	-
		176,539	176,539
Creditors: amounts falling due within one year		-	-
Net current assets		176,539	176,539
Total assets less current liabilities		176,539	176,539
Net assets		176,539	176,539
Capital and reserves			
Called up share capital	3	10,000	10,000
Profit and loss account	4	166,539	166,539
Shareholders' funds		176,539	176,539

The company did not trade during the current or preceding period and has made neither profit nor loss, nor any other comprehensive income.

No significant accounting transactions as defined by section 1169 of the Companies Act 2006 occurred in the current period. For the period ending 30 June 2022, the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.

For the period ending 30th June 2022 the company was entitled to exemption from audit under section 480 of the Companies Act 2006 relating to dormant companies.



BIOLINE PRODUCTION LIMITED

Registered number: 02050016

STATEMENT OF FINANCIAL POSITION as at 30 June 2022 (continued)

Directors' responsibilities:

- the members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476
- the directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

These financial statements on pages 4 to 7 were approved by the board of directors on and were signed on its behalf by:



L. POKORNY
Director

BIOLINE PRODUCTION LIMITED

Registered number: 02050016

NOTES TO THE FINANCIAL STATEMENTS for the 9 months ended 30 June 2022

1. Principal accounting policies

Bioline Production Limited (the "Company") is a company limited by shares and incorporated and domiciled in the UK.

These financial statements were prepared in accordance with Financial Reporting Standard 102, *The Financial Reporting Standard* applicable in the UK and Republic of Ireland ("FRS 102"). The functional and presentation currency of these financial statements is sterling.

Measurement convention

The financial statements are prepared in accordance with the historical cost convention.

Foreign currency

Monetary assets and liabilities denominated in foreign currencies at the year end are reported at the rates of exchange prevailing at that date. Transactions denominated in foreign currencies are recorded in the local currency at the actual or average rates where these approximate the actual rate at the date of the transaction. All differences are taken to the statement of comprehensive income.

Taxation

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Tangible fixed assets

Fixed assets are stated at cost less accumulated depreciation.

Depreciation is calculated so as to write off the cost of tangible fixed assets, less their estimated residual values, on a straight line basis over the expected useful economic lives of the assets concerned, commencing after the asset is brought into use. The principal annual rates used for this purpose are:

	%
Buildings	5 - 12
Plant and equipment	8 - 33

Impairment of tangible fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

Short-term debtors and creditors

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the statement of comprehensive income in other operating expenses.

Provisions

A provision is recognised when the company has a legal or constructive obligation as a result of a past event and it is probable that an outflow of economic benefit will be required to settle the obligation.

Provisions are measured at the best estimate (including risks and uncertainties) of the expenditure required to settle the present obligation. The effect of the time value of money is not material and therefore the provisions are not discounted.

BIOLINE PRODUCTION LIMITED

Registered number: 02050016

2. Debtors

	30 June 2022	30 September 2021
	£	£
Amounts falling due within one year		
Amounts due from other group undertakings	176,539	176,539
	176,539	176,539

Of the deferred tax asset £nil (2021: £Nil) is expected to reverse after more than one year.

3. Called up share capital

	30 June 2022	30 September 2021
	£	£
Allotted, called up and fully paid		
10,000 ordinary shares of £1 each	10,000	10,000

4. Reserves

Called-up share capital

This reserve records the nominal value of shares that have been issued.

Profit and loss account

This reserve records all current and prior year retained profits and losses less dividends paid.

5. Contingent liabilities

HMRC have opened enquiries into Syngenta Holdings Limited for the years from 2011 to 2017 and it is anticipated that enquiries will be opened into 2018 and 2019. As Syngenta Bioline Limited and Syngenta Bioline Production Limited claimed group relief from Syngenta Holdings Limited, if the outcome of the enquiry impacts the losses available for surrender, additional tax could be payable by Syngenta Bioline Limited and Syngenta Bioline Production Limited. Any tax in respect of these liabilities will be Syngenta Holdings Limited's responsibility under the terms of the sale and purchase agreement.

6. Ultimate holding company

The immediate parent company is Bioline Agrosiences Ltd, incorporated in Great Britain and registered in England and Wales.

The directors regard Invivo Group SAS, a company incorporated in France, as the group's ultimate parent undertaking and controlling party. Invivo Group SAS is also the parent of the largest and smallest group for which consolidated financial statements that include the results of Bioline Production Limited are prepared. Copies of the group consolidated financial statements may be obtained from Invivo Group SAS, 83 Avenue de la Grande Armée, 75016 Paris 16e, France.